Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTALON – [68Ga]Ga-PentixaFor PET for lateralization of aldosterone secretion in primary aldosteronism
2023-505507-22-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of pentixafor in primary aldosteronism (PA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Higher SUVmax between adrenal glands, Adrenal SUVmax ratio and 2 more. Started Mar 2024; status: completed.
02
Drugs
pentixafor
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on 2023-505507-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505507-22-00.